Introduction
============

Nasopharyngeal carcinoma (NPC) is endemic in China, where over 33000 new cases were diagnosed in 2012, which represented 40% of new NPC cases worldwide [@B1]. Radiotherapy is the primary treatment modality for NPC [@B2], [@B3]. Staging can provide important information when formulating treatment plans and estimating survival in NPC [@B4]. According to the current TNM staging system, T classification is based on the anatomical extent of the primary tumor and has been proven to reflect the risk of local failure [@B4], [@B5]. In particular, involvement of the paranasal sinuses, which include the sphenoid sinus, ethmoid sinus, maxillary sinus and frontal sinus, are important landmarks of local tumor extension surrounding the nasopharynx in the anterior and superior directions. The reported incidence of paranasal sinus invasion is as high as 23.6%-27.0% [@B6]-[@B9].

However, there is no uniform consensus regarding staging of paranasal sinus invasion in current staging systems. In the 7th edition of the American Joint Committee on Cancer (AJCC) TNM staging system published in 2009, paranasal sinus involvement is one of the staging criteria for T3 disease [@B4]. However, the Chinese 2008 staging system is also commonly used in Southern China - where the incidence of NPC is significantly higher than other regions of the world - and classifies involvement of the paranasal sinuses as T4 disease [@B10].

Another important issue is whether involvement of the four paranasal sinuses, which are different distances from the nasopharynx and adjacent to different critical organs, should be included in the same T classification. Tian et al. investigated a series of patients who were mainly (80.2%) treated by two-dimensional radiotherapy (2D-CRT), and reported no significant differences in the survival outcomes for patients with sphenoid sinus invasion alone and patients with involvement of the ethmoid sinus or maxillary sinus [@B9]. However, in the last few years, intensity-modulated radiotherapy (IMRT) has gradually replaced 2D-CRT as the primary radiotherapy technique for NPC. IMRT provides excellent target conformity and dose coverage. A multicenter phase II trial and large series from a number of different centers have reported IMRT provides superior local control and long-term survival [@B11]-[@B16]. Therefore, the prognostic significance of paranasal sinus invasion may have altered in the IMRT era. In a study to establish a prognostic scoring model for loco-regional control in patients with NPC treated with IMRT, Tao et al. reported that involvement of the ethmoid sinus or maxillary sinus was associated with a significantly higher risk of loco-regional relapse compared to sphenoid sinus invasion [@B8]. However, to the best of our knowledge, the appropriate staging for paranasal sinus invasion has not been comprehensively assessed in the IMRT era. Therefore, we analyzed a large cohort of MRI-staged patients treated with IMRT in the endemic area to investigate the optimal classification for paranasal sinus invasion in the current AJCC staging system for NPC.

Patients and Methods
====================

Patients
--------

All 1811 patients with newly-diagnosed, histologically-proven, non-distant metastatic NPC who completed a full course of IMRT at our institution between December 2009 and February 2012 were retrospectively reviewed. All patients signed an informed consent approved by the ethics committees of our cancer center, and this study was carried out in accordance with the approved ethical guidelines and regulations.The median age of the entire cohort was 45.0 years (range, 14-78 years), with a male-to-female ratio of 2.9:1.

All patients underwent a pretreatment evaluation including a complete patient history, physical examination, hematology and biochemistry profiles, MRI of the neck and nasopharynx, chest radiography, abdominal sonography and whole body bone scan using single photon emission computed tomography (SPECT). Furthermore, positron emission tomography-computed tomography (PET-CT) was performed on 528/1811 (29.2%) patients. Medical records and imaging studies were analyzed retrospectively, and all patients were staged according to the 7th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) system [@B4]. The characteristics of the patients analyzed in this study are shown in Table [1](#T1){ref-type="table"}.

Imaging
-------

The region from the suprasellar cistern to the suprasternal notch were examined with a 1.5-T MRI system (Signa CV/i; General Electric Healthcare, Chalfont St. Giles, United Kingdom). Firstly, axial, coronal and sagittal T1- weighted (repetition time \[TR\]/echo time \[TE\], 500-600 ms/10-20 ms), and axial T2-weighted (TR/TE, 4,000-6,000/95-110 ms) fast spin-echo MR images were obtained. Secondly, gadopentetate dimeglumine (0.1 mmol/kg; Magnevist, Schering, Berlin, Germany) was injected intravenously. Then axial and sagittal spin-echo T1-weighted and coronal spin-echo T1-weighted fat-suppressed sequences were obtained. Further details regarding MR imaging techniques in our center have been reported previously [@B9], [@B15]. All MRI scans were reviewed jointly by two radiologists with more than 10 years\' experience in head and neck cancer MRI. Paranasal sinuses involvement was diagnosed using the following criteria: (1) extension of primary tumor into the sinus cavity with sinus wall destruction; and (2) the lesion in the sinuses had the same signal intensity characteristics as the primary tumor. [@B9] The anatomical sites of the paranasal sinuses are shown in Figure [1](#F1){ref-type="fig"}.

Treatment
---------

The nasopharyngeal and neck tumor volumes of all patients were treated using radical radiotherapy based on IMRT for the entire treatment course. Target volumes were delineated slice-by-slice on treatment planning CT scans using an individualized delineation protocol that complies with International Commission on Radiation Units and Measurements reports 50 and 62. The prescribed doses were 66-72 Gy at 2.12-2.43 Gy/fraction (with 4.5% of patients over 2.33 Gy/fraction for they enrolled in a clinical trial in our center) to the planning target volume (PTV) of the primary gross tumor volume (GTVnx), 64-70 Gy/ 28-33 fractions to the PTV of the GTV of the involved lymph nodes (GTVnd), 60-63 Gy/ 28-33 fractions to the PTV of the high-risk clinical target volume (CTV1), and 54-56 Gy/ 28-33 fractions to the PTV of the low-risk clinical target volume (CTV2). The plan could be accepted if the prescribed dose encompassed at least 95% of the target volume. All targets were treated simultaneously using the simultaneous integrated boost technique; other details of the techniques used at our center have previously been reported [@B12].

During the study, institutional guidelines recommended radiotherapy alone for stage I and concurrent chemoradiotherapy ± neoadjuvant /adjuvant chemotherapy for stage II to IVB. In total, 93.5% (1244/1330) of patients with stage III-IVB NPC received concurrent chemoradiotherapy ± neoadjuvant/adjuvant chemotherapy. When possible, salvage treatments (intracavitary brachytherapy, surgery or chemotherapy) were provided in documented relapse or persistent disease.

Follow-up
---------

Each patient was assessed for treatment response and toxicity every week during treatment, every 3 months during the first 2 years after radiotherapy and every 6 months during years 3-5. Patients with residual or recurrent local disease underwent biopsy to confirm malignancy. CT, MRI, or PET-CT was used for diagnosis of residual/ recurrent disease if biopsy was not feasible. Additional tests were ordered when indicated to evaluate for local or distant failure.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). The outcome of interest was local relapse-free survival (LRFS). LRFS was calculated from the first day of treatment to the first local relapse. Survival rates were calculated using the Kaplan-Meier method and compared using the log-rank test [@B17]. Multivariate analyses with the Cox proportional hazards model were used to calculate hazard ratios (HRs), 95% confidence intervals (CIs) and test the independent significance of different factors by backward elimination of insignificant variables [@B18], and included host factors (sex, age), pathological type (keratinizing squamous cell carcinoma vs. non-keratinizing carcinoma), chemotherapy, and tumor factors (skull base erosion, hypopharyngeal extension, orbit extension, masticator space extension, cranial nerve palsy and intracranial extension; N category) as covariates. Two-tailed *P*-values \< 0.05 were considered statistically significant.

Results
=======

Incidence of paranasal sinus invasion
-------------------------------------

The incidence of paranasal sinus invasion was 16.0% (289 of 1811 patients), with invasion of the sphenoid sinus, ethmoid sinus and maxillary sinus observed in 271 (15.0%), 89 (4.9%) and 76 (4.2%) of the 1811 patients, respectively. No patients had frontal sinus invasion. Of the 271 patients with sphenoid sinus invasion, 104 (38.1%) also had ethmoid sinus or maxillary sinus invasion. Of the 89 patients with ethmoid sinus invasion and 76 patients with maxillary sinus invasion, 65 (85.5%) and 79 (88.8%), respectively, also had sphenoid sinus invasion. According to the T classification of the seventh edition of the AJCC staging system, of the 289 patients with paranasal sinus invasion, 95 (32.9%) had T3 disease and 194 (67.1%) had T4 disease. The distribution of paranasal sinus invasion by T classification is shown in Table [2](#T2){ref-type="table"}.

Prognosis of patients with paranasal sinus invasion
---------------------------------------------------

The median follow-up period was 38.3 months for the entire cohort (range, 1.3-60.2 months). For patients alive at last follow-up, 0.7% (14/1811) and 2.0% (36/1811) had a follow-up time of less than 12 and 24 months, respectively. A total of 79/1811 (4.4%) patients developed local failure. The 3-year LRFS rate for the entire cohort was 95.7%.

We explored the prognostic value of sphenoid sinus, ethmoid sinus and maxillary sinus invasion in NPC. Univariate analysis identified sphenoid sinus, ethmoid sinus and maxillary sinus invasion as prognostic factors for 3-year LRFS (91.2% vs. 96.5%; 80.1% vs. 96.5%; and 78.5% vs. 96.5%, respectively, all *P*\< 0.001), with better outcomes in patients without sphenoid sinus, ethmoid sinus or maxillary sinus invasion, respectively. The corresponding Kaplan-Meier survival curves are shown in Figure [2](#F2){ref-type="fig"}.

Multivariate analysis was performed to adjust for confounding factors. Both ethmoid sinus invasion (HR, 2.889; 95% CI, 1.362-6.131; *P* = 0.006) and maxillary sinus invasion (HR, 3.110; 95% CI, 1.439-6.721; *P* = 0.004) were found to be independent prognostic factors for LRFS, while sphenoid sinus invasion had no effect on local failure (HR, 0.753; 95% CI, .338-1.673; *P* = 0.49).

Grading and staging categories for paranasal sinus involvement
--------------------------------------------------------------

Due to the proximity of the floor of the sphenoid sinus to the roof of the nasopharynx, and as the majority of patients with maxillary sinus or ethmoid sinus invasion also had sphenoid sinus invasion, we classified paranasal sinus invasion into two grades: grade 1, sphenoid sinus invasion alone (*n* = 167); and grade 2, ethmoid sinus or maxillary sinus invasion with or without sphenoid sinus invasion (*n* = 122). Significant differences in 3-year LRFS were observed between grade 1 and grade 2 (97.4% vs. 83.1%, *P*\< 0.001). Moreover, the grade of paranasal sinus invasion retained independent prognostic value for local failure in multivariate analyses (HR, 2.010; 95% CI, 1.526-2.649; *P*\< 0.001).

Next, to investigate the significance of paranasal sinus invasion in NPC with respect to the seventh AJCC staging system, we divided patients with T3-4 disease into four subgroups as follows: group 1, T3 disease without paranasal sinus invasion (*n*= 770); group 2, T3 disease with sphenoid sinus invasion alone (*n* = 63); group 3, T3 disease with ethmoid sinus or maxillary sinus invasion (*n* = 32); and group 4, T4 disease (*n* = 337). Kaplan-Meier survival curves for these four subgroups were shown in Figure [3](#F3){ref-type="fig"}. T3 patients with ethmoid sinus or maxillary sinus invasion had no significant differences in 3-year LRFS (83.6% vs. 92.2%, *P*= 0.13) compared with T4 patients, and had an increased risk of local failure compared to T3 patients without paranasal sinus invasion (83.6% vs. 96.4%, *P*\< 0.001). However, T3 patients with sphenoid sinus invasion alone had similar 3-year LRFS (98.3 vs. 96.4%, *P*= 0.39) to T3 patients without paranasal sinus invasion, and demonstrated a trend towards higher 3-year LRFS than T4 patients (98.3% vs. 92.2%, *P* = 0.06).

Discussion
==========

Uniform consensus has not yet been reached on appropriate staging for invasion of the paranasal sinuses. In the current edition of the AJCC staging system for NPC, paranasal sinus invasion is included in the T3 classification [@B4]. However, in the Chinese 2008 staging system, which is widely used in China where NPC is endemic, paranasal sinus invasion is classified as T4 disease [@B10]. Controversy also exists whether the involvement of different paranasal sinuses should be included in the same T classification. Tao et al. reported that involvement of the ethmoid sinus or maxillary sinus were associated with a higher risk of loco-regional relapse compared to involvement of the sphenoid sinus in patients with NPC treated with IMRT [@B8]. Thus, staging for involvement of the paranasal sinuses in NPC requires further investigation.

In this study, we retrospectively analyzed a large cohort of patients treated with IMRT and found that involvement of the ethmoid sinus or maxillary sinus was associated with a higher risk of local failure than sphenoid sinus invasion alone. T3 disease with ethmoid sinus or maxillary sinus invasion had similar LRFS rate as T4 disease, while the LRFS rate for T3 disease with involvement of the sphenoid sinus alone were comparable to T3 disease without paranasal sinus invasion. Thus, we suggest that involvement of different paranasal sinuses should be grouped into different T classifications; patients with sphenoid sinus invasion alone should be classified as T3 disease whereas patients with involvement of the ethmoid sinus or maxillary sinus should be classified as T4 disease.

In the fifth edition of the AJCC staging system for NPC published in 1997, paranasal sinus invasion was defined as T3 disease [@B19], and this classification remained in the sixth and current seventh edition [@B4], [@B20]. However, imaging and treatment techniques for NPC have undergone tremendous changes in the last two decades. MRI has been proven to be superior to computed tomography (CT) for assessing the tumor extent and has become the imaging modality of choice [@B21]-[@B23]. Additionally, radiotherapy techniques have evolved from 2D-CRT to IMRT [@B11]-[@B16]. Thus, the staging criteria - including paranasal sinus invasion - established in patients diagnosed and treated using older technologies need to be reassessed in the new era. To the best of our knowledge, this is the first study to assess the staging of paranasal sinus invasion in patients with NPC treated with IMRT; this study may provide useful information for future revisions of the current AJCC staging system.

Previous studies have demonstrated the predictive role of tumor volume for treatment outcome in NPC. Patients with a larger primary tumor volume were reported to have an increased risk of local failure [@B24], [@B25]. Due to the proximity of the floor of the sphenoid sinus to the roof of the nasopharynx, and the fact the majority of patients with ethmoid sinus (85.5%) or maxillary sinus invasion (88.8%) also had sphenoid sinus invasion, it is reasonable to speculate that the primary tumor volume of patients with sphenoid sinus invasion alone might be smaller than that of patients with ethmoid sinus or maxillary sinus invasion. Therefore, tumor volume may be an intrinsic factor that explains why patients with sphenoid sinus invasion have a more favorable outcome than patients with ethmoid sinus or maxillary sinus invasion.

In terms of the prevalence of paranasal sinus invasion, sphenoid sinus invasion had the highest rate (15%), followed by ethmoid sinus invasion (4.9%) and maxillary sinus invasion (4.2%). As local disease spreads in a stepwise manner from proximal to distal sites and the sphenoid sinus borders the roof of the nasopharynx, sphenoid sinus invasion has the highest rate of incidence, and invasion of more distal sites such as the ethmoid sinus or maxillary sinus frequently occurs simultaneously to sphenoid sinus invasion (85.5% and 88.8%, respectively). Compared to the respective rates of 21-27%, 5-9%, and 4%-14% reported in other studies [@B6]-[@B9], the rate of sphenoid sinus invasion was lower in the current study. Instead of a genuine imbalance in patient composition among these large cohorts, it is more likely that variations in the diagnostic criteria for paranasal sinus invasion used by radiologists may explain this inconsistency. While there should be minimal discrepancy in the diagnosis of gross paranasal sinus invasion, subtle invasion of the paranasal sinus is not uncommon, and may pose both a diagnostic challenge and a source of variation between different centers or individual radiologists [@B26].

It should be stressed this study has some limitations. Firstly, there were unavoidable biases due to the retrospective nature of the study. Secondly, as 46.4% (840/1811) of patients underwent induction chemotherapy before radiotherapy, data on the primary tumor volume was not available. Thus, we can only speculate that a smaller tumor volume may be the factor underlying the more favorable outcome of patients with sphenoid sinus alone. Thirdly, this study only included patients from the endemic region in China, of whom only 2% had keratinizing disease (WHO type I), which accounts for up to 67% of cases of NPC in western countries [@B27]. Thus the results of the current study need to be confirmed in further studies of other cohorts from different regions before they can be generalized to all patients with NPC.

In conclusion, patients with ethmoid sinus or maxillary sinus invasion had a higher risk of local failure than those with sphenoid sinus invasion alone. Patients with sphenoid sinus invasion alone should be classified with T3 disease and those with involvement of the ethmoid sinus or maxillary sinus as T4 disease in the current AJCC staging system for NPC.
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![The paranasal sinuses, which include the sphenoid sinus, ethmoid sinus, maxillary sinus and frontal sinus, are important anatomical structures that surround the nasopharynx in the anterior and superior directions. Abbreviations: SS = sphenoid sinus; ES = ethmoid sinus; MS = maxillary sinus; FS = frontal sinus; NP = nasopharynx.](jcav07p1353g001){#F1}

![Kaplan-Meier local relapse-free survival curves for patients with NPC stratified by involvement of the sphenoid sinus (**A**), ethmoid sinus (**B**), and maxillary sinus (**C**), respectively. Abbreviations: 3-y = 3-year; LRFS = local relapse-free survival; SS = sphenoid sinus; ES = ethmoid sinus; MS = maxillary sinus.](jcav07p1353g002){#F2}

![Probability of local relapse-free survival for patients with T3 disease and patients with T4 disease according to the current AJCC staging system. Group 1 = patients with T3 disease without paranasal sinus invasion, Group 2 = patients with T3 disease with sphenoid sinus invasion alone, Group 3 = patients with T3 disease with ethmoid sinus or maxillary sinus invasion and Group 4 = patients with T4 disease. 3-y = 3-year; LRFS = local relapse-free survival.](jcav07p1353g003){#F3}

###### 

Clinicopathological characteristics of 1811 patients with nasopharyngeal carcinoma stratified by the presence or absence of paranasal sinus invasion.

  Characteristic                         No. of 1522 patients without paranasal sinus invasion   No. of 289 patients with paranasal sinus invasion   *P*
  -------------------------------------- ------------------------------------------------------- --------------------------------------------------- ----------
  **Gender**                                                                                                                                         0.29
  Male                                   1128                                                    223                                                 
  Female                                 394                                                     66                                                  
  **Age (years)**                                                                                                                                    0.12
  \< 50                                  1056                                                    187                                                 
  ≥ 50                                   466                                                     102                                                 
  **Histological type ^a^**                                                                                                                          0.22
  Keratinizing squamous cell carcinoma   7                                                       3                                                   
  Non-keratinizing carcinoma             1515                                                    286                                                 
  **Chemotherapy**                                                                                                                                   \< 0.001
  Yes                                    1276                                                    276                                                 
  No                                     246                                                     13                                                  
  **T-category^b^**                                                                                                                                  \< 0.001
  T1                                     326                                                     0                                                   
  T2                                     283                                                     0                                                   
  T3                                     770                                                     95                                                  
  T4                                     143                                                     194                                                 
  **N-category^b^**                                                                                                                                  0.001
  N0                                     277                                                     31                                                  
  N1                                     881                                                     181                                                 
  N2                                     218                                                     58                                                  
  N3a                                    26                                                      6                                                   
  N3b                                    120                                                     13                                                  
  **Stage-group^b^**                                                                                                                                 \< 0.001
  I                                      99                                                      0                                                   
  II                                     382                                                     0                                                   
  III                                    770                                                     87                                                  
  IVa                                    151                                                     189                                                 
  IVb                                    120                                                     13                                                  

^a^ According to the 2005 World Health Organization classification of tumors.

^b^According to the 7^th^ UICC/AJCC staging system.

###### 

Distribution of paranasal sinus invasion in 1811 patients with nasopharyngeal carcinoma by T classification.

       SS+, MS-, ES-   MS+, SS-, ES-   ES+, SS-, MS-   SS+, MS+, ES-   SS+, ES+, MS-   MS+, ES+, SS-   SS+, MS+, ES+
  ---- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  T3   63              7               4               4               9               2               6
  T4   104             1               3               21              30              1               34

Abbreviations: SS = sphenoid sinus; ES = ethmoid sinus; MS = maxillary sinus.

###### 

Multivariate analysis of prognostic factors in 1811 patients with nasopharyngeal carcinoma.

  Endpoint                         Variable                                                                                      HR (95% CI)            *P*-value ^a^
  -------------------------------- --------------------------------------------------------------------------------------------- ---------------------- ---------------
  Local recurrence-free survival   Histological type ^b^ (keratinizing squamous cell carcinoma vs. non-keratinizing carcinoma)   7.242 (1.768-29.662)   0.006
                                   Ethmoid sinus invasion                                                                        2.889 (1.362-6.131)    0.006
                                   Maxillary sinus invasion                                                                      3.110 (1.439-6.721)    0.004
  Overall survival                 Age (\< 50 vs. ≥ 50)                                                                          1.946 (1.359-2.785)    \< 0.001
                                   N classification ^c^ (N0-1 vs. N2-3)                                                          3.961 (2.760-5.685)    \< 0.001
                                   Skull base invasion                                                                           1.946 (1.217-3.111)    0.005
                                   Maxillary sinus extension                                                                     2.614 (1.455-4.695)    0.001

Abbreviations: HR = hazard ratio; CI = confidence interval.

^a^*P*-values were calculated using an adjusted Cox proportional hazards model.

^b^ According to the 2005 World Health Organization classification of tumors.

^c^According to the 7th UICC/AJCC staging system.
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